$40 Million

Nexvet Biopharma

Initial Public Offering

Bookrunner, February 2015

Nexvet is a global clinical-stage biopharmaceutical company focused on transforming the therapeutic market for companion animals. The Company develops and commercializes novel biologic therapies, including “100% species-specific” products derived from its PETization™ technology. The Company’s most advanced product candidate, ranevetmab, is a monoclonal antibody being developed as a monthly subcutaneous injectable for the control of pain associated with osteoarthritis in dogs.